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Although it is currently recognized that bronchial asthma is not a single disease but a syndrome, we have
not yet made use of our new understanding of this heterogeneity as we treat asthma patients. To increase
the efﬁcacy of anti-asthma drugs and to decrease costs, it is important to stratify asthma patients into
subgroups and to develop therapeutic strategies for each subgroup. Periostin has recently emerged as a
biomarker for bronchial asthma, unique in that it is useful not in diagnosis but in categorizing asthma
patients. We ﬁrst found that periostin is a novel component of subepithelial ﬁbrosis in bronchial asthma
downstream of IL-13 signals. Thereafter, it was shown that periostin can be a surrogate biomarker of type
2 immune responses, the basis of the notion that a detection system of serum periostin is potentially a
companion diagnostic for type 2 antagonists. Furthermore, we have recently shown that serum periostin
can predict resistance or hyporesponsiveness to inhaled corticosteroids, based on its contribution to
tissue remodeling or ﬁbrosis in bronchial asthma. Thus, serum periostin has two characteristics as a
biomarker for bronchial asthma: it is both a surrogate biomarker of type 2 immune responses and a
biomarker reﬂecting tissue remodeling or ﬁbrosis. We can take advantage of these characteristics to
develop stratiﬁed medicine in bronchial asthma.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
It is now recognized that bronchial asthma is not a single disease
but a syndrome.1 Clinicians have empirically been aware of the
heterogeneity of bronchial asthma for a long time. Many fac-
torsdage of onset, obesity, types of inﬂammatory cells, IgE-
dependency, and responsiveness to inhaled corticosteroids
(ICS)dlead to the heterogeneity of bronchial asthma. But as we
consider treatments for asthma patients, we have not yet taken into
account the heterogeneity of the disease; severity has been the
most important factor in deciding on treatment.2 For example, we
increase the ICS dose according to severity, and for the most
severely ill patients, we have other options such as oral steroids or
anti-IgE antibodies. But it is now questionable whether this is the
best strategy.emistry, Department of Bio-
shima, Saga 849-8501, Japan.
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rgology. Production and hosting by ElseICS is recognized as a very effective therapeutic agent for
bronchial asthma, signiﬁcantly decreasing the number of asthma
deaths. However, 5e10% of asthma patients are resistant to ICS
treatment.3,4 Although the percentage is relatively small, these
patients account for about 50% of the total medical cost of treating
asthma patients. It has been reported that the effectiveness of anti-
IgE antibodies for severe asthma patients is at most 60%.5 Although
anti-IgE antibodies recognize IgE, serum IgE levels cannot predict
responsiveness. Moreover, biologics including anti-IgE antibodies
are very expensive. So it is important to stratify patients into sub-
groups showing good or poor responsiveness to ICS or anti-IgE
antibodies and to develop a strategy to administer ICS as the
ﬁrst-line agent and oral corticosteroids or anti-IgE antibodies as
second-line agents. Development of stratiﬁed medicine in bron-
chial asthma would both increase the efﬁcacy of anti-asthma drugs
and decrease treatment costs.
Periostin has recently emerged as a biomarker for bronchial
asthma.6 Biomarkers have been mainly developed to diagnose
diseases. However, periostin is a unique biomarker in that it is not
used for diagnosis but for categorizing asthma patients. Diagnostics
to predict the efﬁcacy of drugs are now called “companionvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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system would have the potential to be a companion diagnostic for
anti-asthma drugs. In this article, we focus on the characteristics of
periostin as an inﬂammatory mediator of bronchial asthma and the
usefulness of measuring periostin in the treatment of bronchial
asthma. We recommend another review article for the overall
characteristics of periostin and the functional roles of periostin in
allergic diseases.7
History of the development of stratiﬁed medicine in bronchial
asthma
Anti-IL-5 antibodies
Trials for development of stratiﬁed medicine in bronchial
asthma beganwith anti-IL-5 antibodies, although it is doubtful that
the present strategy involving these antibodies was intended from
the beginning. IL-5 is a signature cytokine of type 2 immune re-
sponses produced mainly in Th2 cells and group2 innate lymphoid
cells (ILC2).8,9 IL-5 primarily induces the development and expan-
sion of eosinophil lineage cells. Its importance in the pathogenesis
of bronchial asthma was established in the 1990s mainly through
analyses of IL-5edeﬁcient mice.10 Based on these ﬁndings, anti-IL-5
antibodies were developed as anti-asthma drugs, and these agents
were used in several clinical trials. However, the initial results were
disappointing; although peripheral eosinophils decreased, lung
functions were not improved by administering anti-IL-5 anti-
bodies.11,12 These results seem reasonable now because asthma
patients are known to be heterogeneous, and molecularly targeted
drugs such as anti-IL-5 antibodies would be effective only for some
fraction of asthma patients, not for all. However, no stratiﬁcation
was performed in those trials. Thereafter, the strategy for devel-
opment of an anti-IL-5 antibody called mepolizumab as an anti-
asthma drug was changed, targeting steroid-resistant asthma pa-
tients showing high eosinophil numbers in sputum or blood,
because it was assumed that sputum or blood eosinophils reﬂected
IL-5 levels as a surrogate marker of IL-5. This strategy was suc-
cessful, demonstrating that mepolizumab decreased exacerbation
of asthma in stratiﬁed patients.13,14 A phase III study ofAntagonists Manufacture
IL-4 mutein (Pitrakinra) Bayer/AEROVANCE
 Amgen
Pfizer
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Fig. 1. The status of IL-4/IL-13 antagonists as anti-asthma agents. IL-4/IL-13 antagonists thamepolizumab has recently been reported, showing that mepoli-
zumab has a glucocorticoid-sparing effect, reduces exacerbations,
and improves asthma symptoms.15,16 This study is the ﬁrst example
of development of stratiﬁed medicine in bronchial asthma.
IL-4/IL-13 antagonists
The importance of IL-4 and IL-13, other signature cytokines of
type 2 immune responses, in the pathogenesis of bronchial asthma
was established in the 1990s using model mice, as had been done
with IL-5.17e19 In particular, IL-13 plays a central role in patho-
genesis because compared with IL-4, it is abundantly expressed in
inﬂamed lesions.20 IL-4 and IL-13 are related cytokines sharing a
receptor (type II IL-4 receptor/IL-13 receptor) and signal pathways
via the receptor. Based on these ﬁndings, antagonists against IL-13,
or both IL-13 and IL-4, have been developed as anti-asthma drugs.
However, some antagonists have shown satisfactory results,
whereas others were withdrawn for low efﬁcacy (Fig. 1).21e26 This
can again be explained by the heterogeneity of asthma patients;
some patients are responsive to IL-4/IL-13 antagonists, whereas
others are not. Among several clinical trials, the Roche/Genentech
group adopted a fruitful strategy.21 They applied serum periostin as
a surrogate biomarker of in vivo IL-13 production and examined the
efﬁcacy of an anti-IL-13 antibody called lebrikizumab for stratiﬁed
patients. They found that lebrikizumab showed good efﬁcacy for
high periostin patients, whereas it did not for low periostin pa-
tients. This study should be appreciated as a milestone in the
development of stratiﬁed medicine for bronchial asthma.
A Sanoﬁ group has recently published the results of a clinical
trial of an anti-IL-4 receptor a chain antibody called dupilumab
using peripheral or sputum eosinophils for stratiﬁcation of asthma
patients.23 Hanania and colleagues have shown the usefulness of
peripheral eosinophil number, fractional exhaled nitric oxide
(FeNO), and periostin to predict the efﬁcacy of anti-IgE antibodies
(omalizumab).27 More than half of the anti-asthma drugs under
development are antagonists against type 2 immune responses
(Fig. 2). Therefore, it is a very important issue in the establishment
of stratiﬁed medicine for bronchial asthma to identify which
biomarker is the most useful to reﬂect type 2 immune responses+ + phase IIa
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Fig. 2. Anti-asthma drugs to target type 2 responses. All anti-asthma drugs under development targeting type 2 responses are listed from the websites.
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FeNO, and periostin.Discovery of periostin as a novel mediator of allergic airway
inﬂammation
IL-13 is a multifunctional cytokine acting on both immune
cellsdB cells, macrophages, eosinophils, basophils and mast
cellsdand non-immune cellsdepithelial cells, endothelial cells,
ﬁbroblasts, and smooth muscle cells.20 Several lines of evidence
have shown that the actions of IL-13 on bronchial epithelial cells are
important in enhancing airway hyper-reactivity, a key feature of
bronchial asthma.28,29 To clarify the roles of IL-13 on human
bronchial epithelial cells, we conducted a thorough search for IL-
13einducible genes using the DNAmicroarraymethod, ﬁnding that
periostin is one of the highly expressed genes.30 When we found
these results, no relationship between periostin and inﬂammation
or lung tissues had yet been reported.H&E staining
Thickened Basement Membrane
Fig. 3. Involvement of periostin in thickness of basement membrane in bronchial asthma (ci
asthma patients.We then investigated how periostin is involved in the patho-
genesis of bronchial asthma. Using immunohistochemical ana-
lyses, we found that in asthma patients, periostin is deposited on
the thickened basement membrane, suggesting that it is a
component of subepithelial ﬁbrosis in bronchial asthma
(Fig. 3).31,32 We conﬁrmed that deposition of periostin is depen-
dent on IL-4 and/or IL-13 signals: periostin deposition was
signiﬁcantly decreased in IL-4 or IL-13 deﬁcient mice. This was the
ﬁrst formal evidence that periostin is involved in the pathogenesis
of bronchial asthma.
Thereafter, Fahy and colleagues showed that periostin can be a
surrogate biomarker of type 2 immune responses.33,34 They clas-
siﬁed asthma patients into “Th2-high” and ”Th2-low” asthma based
on expression of IL-13 and IL-5. The proportion of Th2-high asthma
is estimated to be 50e70% of adult asthma.34,35 They comprehen-
sively searched for signature molecules of these two types of
asthma, ﬁnding that periostin as well as chloride channel regulator
1 and serpin peptidase inhibitor, clade B, member 2, is a signature
molecule of “Th2-high” asthma. This ﬁnding led to the applicationPeriostin staining
Periostin
ted from Reference 31). Periostin is deposited on the thickened basement membrane in
Fig. 5. Advantages of periostin as a biomarker.
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rikizumab study by the Roche/Genentech group.21
The pathological role of periostin in asthma has not yet been
established. Several initial studies using periostin-deﬁcient mice
showed that periostin acts as a protective molecule against allergic
airway inﬂammation.36,37 However, it has been recently reported
that periostin accelerates allergic airway inﬂammation, using
periostin-deﬁcient mice and neutralizing antibodies against peri-
ostin.38 This discrepancy may be due to differences in the experi-
mental protocols. We have recently evaluated the change in
pulmonary functions of 20 asthma patients more than 20 years
after they were ﬁrst diagnosed with asthma.39 We found that the
degree of periostin deposition in biopsy samples obtained when
they were diagnosed 20 years ago is inversely associated with their
subsequent change in pulmonary function (Fig. 4), which supports
the idea that periostin is an accelerator for bronchial asthma.
Usefulness of periostin as a biomarker for bronchial asthma
Advantages of periostin as a biomarker
We assume that serum periostin has several advantages as a
biomarker (Fig. 5). Firstly, periostin is likely to have a tendency to
move easily from the affected lesions to vessels. Three types of
cellsdepithelial cells, ﬁbroblasts, and endothelial cellsdare
possible periostin sources in bronchial asthma.31,40,41 It is unsure
how each type of cell contributes to up-regulation of serum peri-
ostin in asthma patients. Periostin produced in epithelial cells or
ﬁbroblasts may easily migrate into the vessels. Alternatively, peri-
ostin produced in endothelial cells may be directly secreted into the
vessels. Interestingly, it is likely that little to no periostin is secreted
into bronchial lumens.42 Secondly, the basal level of serum peri-
ostin (~50 ng/ml) is likely appropriate as a serum biomarker. The
serum levels of other ECM proteins such as ﬁbronectin or vitro-
nectin (~100 mg/ml) are much higher than that of periostin, which
means that if the same amounts of ECM proteins migrate into
vessels, increase of periostin can be easily reﬂected in serum per-
iostin levels, compared to other ECM proteins. On the other hand,
serum levels of cytokines including IL-13 (~100 pg/ml) are very low
compared to that of periostin. Although periostin is a downstream
molecule of IL-13 signals, serum IL-13 is not elevated in asthmaPeriostin deposition
in bronchial subepithelium (%)
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Fig. 4. Correlation between periostin deposition and decline of pulmonary function
during 20 years in asthma patients (cited from Reference 39). Degree of periostin
deposition in biopsy samples obtained from patients diagnosed with asthma 20 years
ago is inversely associated with current pulmonary function.patients as serum periostin is.43 Lastly, several high-sensitivity
ELISA kits for periostin are available. Although several commer-
cial or non-commercial ELISA kits are in circulation, the potencies
are diverse; some kits can discriminate eosinophil-dominant
asthma patients, whereas others cannot.43e47 Although other fac-
tors may be involved in this discrepancy, the kit itself is very
important.48 An ELISA kit with a low detection limit has high res-
olution in measuring serum periostin because we can greatly dilute
the sample, decreasing the effects of other serum proteins.
Periostin as a surrogate biomarker of type 2 immune responses
We ﬁrst measured serum periostin in overall asthma patients in
the KiHAC study.44 Serum periostin levels in asthma patients were
signiﬁcantly higher than in normal donors (asthma patients;
n ¼ 224, median: 86.0 ng/mL, average: 92.8 ng/mL, range:
22e312 ng/mL vs. normal donors; n ¼ 66, median: 33.0 ng/mL,
average: 39.1 ng/mL, range: 1e114 ng/mL). However, when the cut-
off value was set at 95 ng/ml, 62% of asthma patients were within
the normal range (Fig. 6). This can be explained by theAsthma patients
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Fig. 6. Serum periostin in overall asthma patients in the KiHAC study (modiﬁed from
Reference 44). Although serum periostin levels in asthma patients are signiﬁcantly
higher than in normal donors, when the cut-off rate was set at 95 ng/ml, 62% of asthma
patients were within the normal range.
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Fig. 8. Correlation between serum periostin and responsiveness to ICS in overall
asthma patients (modiﬁed from Reference 44). Serum periostin is signiﬁcantly higher
in the rapid decliners (poor responders to ICS) than in non-rapid decliners (good re-
sponders to ICS).
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serum periostin levels, whereas others do not. We next examined
what parameter is associated with serum periostin levels, ﬁnding
that late onset, blood eosinophils, serum IgE and ECP levels, and
comorbidity of sinusitis show good correlation with serum peri-
ostin (Fig. 7). The association between high serum periostin and
late onset, high blood eosinophil numbers, and comorbidity of
sinusitis was conﬁrmed independently by Park's group and by
Asano's group.43,45 Furthermore, Park and her colleagues found
that aspirin-intolerant patients show high serum periostin levels.45
This result was conﬁrmed by Asano and his colleagues; when se-
vere asthma patients were divided into high, intermediate, and low
serum periostin groups, the incidence of aspirin intolerance
appeared in that order.43 It is well known that aspirin intolerance
and chronic sinusitis/olfactory dysfunction are complications
characteristic of eosinophil-dominant severe asthma.49 Addition-
ally, we have recently found that FeNO was moderately to strongly
associated with serum periostin in step 4/5 patients, but only
weakly in the overall patients.50 As mentioned before, FeNO is
another biomarker of type 2 immune responses.51,52 Taken
together, these results veriﬁed that serum periostin is a surrogate
biomarker of type 2 immune responses. This forms the basis of the
concept that serum periostin serves as a potential companion
diagnostic for type 2 antagonists.
Periostin as a biomarker to predict hyporesponsiveness to ICS
Given that periostin contributes to tissue remodeling or ﬁbrosis
in bronchial asthma and that ﬁbrosis is one factor causing steroid
resistance in bronchial asthma,53,54 we hypothesized that serum
periostin can predict resistance or hyporesponsiveness to ICS. For
that purpose, in the KiHAC study we divided patients into two
groups, rapid decliners and non-rapid decliners.44 Rapid decliners
were deﬁned as patients showing a decline in FEV1 of more than
30 mL/year, indicating that these patients have some degree of
hyporesponsiveness to ICS. The non-rapid decliners were deﬁned
as patients showing a decline in FEV1 of less than 30mL/year, which
means these patients were good responders to ICS. Serum periostin
was higher in the rapid than in the non-rapid decliners (Fig. 8).
These results suggest that serum periostin is associated with
hyporesponsiveness to ICS in asthma patients overall.
However, the difference of serum periostin between the rapid
and non-rapid decliners was not substantial. We assumed that
since asthma patients are heterogeneous, some patients would
show an association between serum periostin and hypores-
ponsiveness to ICS, but others would not. Therefore, we next tried
to categorize asthma patients and to ﬁnd a subtype showing a good
correlation between serum periostin and hyporesponsiveness to
ICS.55 We categorized asthma patients, based on their peripheral
eosinophil and neutrophil counts, into four groups named clusters
1 to 4 (Fig. 9). Cluster 1, showing low numbers of eosinophils andFig. 7. Characteristics of high periostin asthma.neutrophils characterized as late-onset and non-atopic, were
mostly good responders to ICS. Cluster 2, with high numbers of
eosinophils characterized as early-onset and atopic, were also good
responders to ICS. Cluster 3, showing higher numbers of eosino-
phils than cluster 2, has the characteristics of late-onset and
eosinophil-dominant. The patients in this cluster included many
poor responders to ICS. Cluster 4, with high numbers of neutrophils
and relatively fewer eosinophils than cluster 3, had the character-
istics of the poorest control and high serum IL-6 levels. Most pa-
tients in this cluster were poor responders to ICS. We then
examined the correlation between serum periostin and respon-
siveness to ICS, in terms of changes in pulmonary function, in these
clusters (Fig. 9). The patients in clusters 1 and 2 responded well to
ICS, whereas the patients in cluster 4 were poor responders, irre-
spective of serum periostin. In cluster 3, the difference in DFEV1
between high and low periostin groups was signiﬁcant; the low
periostin patients showed good responsiveness to ICS, whereas the
high periostin patients showed poor responsiveness. Thus, by
combining the categorization of peripheral eosinophil and
neutrophil numbers and serum periostin, we can predict hypo-
responsiveness to ICS in asthma patients.
Based on these results, we propose an algorithm for treating
asthma patients (Fig. 10). We recommend measuring blood eosin-
ophil and neutrophil numbers for the patients in the treatment. It is
expected that if patients belong to clusters 1 or 2, based on these
measurements, they will be good responders to ICS. Next, mea-
surement of serum periostin is highly recommended for cluster 3
and cluster 4 patients. In cluster 3, it can be expected that if they
show low serum periostin, they will respond well to ICS, whereas if
they show high serum periostin, they will be poor responders, with
the background of Th2 inﬂammation, so that additional adminis-
tration of type 2 antagonists should be considered. The patients
belonging to cluster 4 will be poor responders to ICS. It can be
expected that if they show high serum periostin, additional
administration of type 2 antagonists should be considered as in the
case of cluster 3. But if they show low serum periostin, adminis-
tration of other agents should be considered because type 2 an-
tagonists would be ineffective for them.
Fig. 9. Categorization of asthma patients and correlation between serum periostin and responsiveness to ICS in categorized asthma patients (cited from Reference 55). In cluster 3,
deﬁned as asthma patients with high numbers of eosinophils, the low periostin patients show good responsiveness to ICS, whereas the high periostin patients show poor
responsiveness to ICS. The asthma patients in clusters 1 and 2 are good responders to ICS, and the patients in cluster 4 are poor responders to ICS, irrespective of serum periostin.
Fig. 10. Algorithm for treatment of categorized asthma patients. Measurement of blood eosinophil and neutrophil numbers is recommended for the patients in the treatment. The
patients belonging to clusters 1 and 2 would be good responders to ICS. Measurement of serum periostin is highly recommended for both cluster 3 and cluster 4 patients. In cluster
3, the patients showing low serum periostin would be good responders to ICS, whereas the patients showing high serum periostin would be poor responders, so that additional
administration of type 2 antagonists should be considered. Patients in cluster 4 would be poor responders to ICS. Additional administration of type 2 antagonists should be
considered for patients showing high serum periostin, whereas administration of other agents should be considered for those with low serum periostin.
K. Izuhara et al. / Allergology International 64 (2015) S3eS10S8Kato et al. have demonstrated that stable asthma patients
showing high serum periostin are at risk for instability during the
tapering of ICS doses.56 This result is compatible with the notion
that serum periostin, as a biomarker, reﬂects hyporesponsiveness
to ICS.
Prospects
Evidence of the usefulness of serum periostin as a biomarker for
bronchial asthma has recently accumulated. A surrogate biomarker
reﬂecting type 2 immune responses is one characteristic of serum
periostin. We can take advantage of this characteristic to predict
the efﬁcacy of type 2 antagonists. In addition, we have revealed that
periostin, as a biomarker, characteristically reﬂects tissue remod-
eling or ﬁbrosis in bronchial asthma. We can also use thischaracteristic to predict hyporesponsiveness to ICS. We hope to
develop and conﬁrm the usefulness of serum periostin level as a
biomarker for bronchial asthma by performing more clinical
studies. It is crucial to evaluate and compare the characteristics and
usefulness of other surrogate biomarkers of type 2 immune re-
sponses, eosinophils and FeNO, with serum periostin to develop
stratiﬁed medicine in bronchial asthma.
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